Zhongsheng Pharmaceutical Co., Ltd. terminated the research and development project of new stp601

Zhongsheng pharmaceutical announced in the evening of June 5 that stp601 had no therapeutic effect according to the pharmacodynamic research results of pre clinical stp601 In view of the pharmacodynamic confirmation study does not support the therapeutic effect of stp601, the partners agreed to terminate the study of stp601 project after discussion Previously, the fifth meeting of the Fourth Board of directors held on June 10, 2011 reviewed and approved the proposal on the company's investment in stp601 project of class I new drugs, and agreed that the company, Suzhou Shengnuo Biomedical Technology Co., Ltd and sirnamics, Inc of the United States, cooperate to develop stp601 project of class I new drugs for ophthalmology With a capital of no more than 65 million yuan, the company will invest the above funds in stages according to the project schedule Zhongsheng pharmaceutical said that the project is still in the early stage of preclinical research and the company has little investment The termination of the project is the result of the company's risk management and control of the R & D project The R & D of innovative drugs is a high investment and high-risk project, and the R & D risk is inevitable The company will strive to improve the construction of R & D project management system, strengthen the process management and risk control of R & D projects, and ensure the interests of the company and shareholders Announcement of Guangdong Zhongsheng Pharmaceutical Co., Ltd on termination of stp601 new drug research and development project the company and all members of the board of directors guarantee the authenticity, accuracy and integrity of the information disclosure, without false records, misleading statements or major omissions The fifth meeting of the Fourth Board of directors of Guangdong Zhongsheng Pharmaceutical Co., Ltd (hereinafter referred to as "the company") held on June 10, 2011 deliberated and passed the proposal on the company's investment in class I new drug stp601 project, and agreed to cooperate with Suzhou Shengnuo Biomedical Technology Co., Ltd and sirnamics, Inc in the development of class I new drug stp601 project for ophthalmology With a capital of no more than 65 million yuan, the company will invest the above-mentioned capital in stages according to the project schedule For details, please refer to the relevant announcements of the company published in the securities times and cninfo.com on June 13, 2011 According to the results of preclinical pharmacodynamic study of stp601, stp601 showed no therapeutic effect In view of the pharmacodynamic confirmation study does not support the therapeutic effect of stp601, the partners agreed to terminate the study of stp601 project after discussion The project is still in the early stage of preclinical research, and the company has little investment The termination of the project is the result of the company's risk management and control of the R & D process The R & D of innovative drugs belongs to high investment and high-risk projects, and the R & D risks are inevitable The company will strive to improve the construction of R & D project management system, strengthen the process management and risk control of R & D projects, and ensure the interests of the company and shareholders It is hereby announced The board of directors of Guangdong Zhongsheng Pharmaceutical Co., Ltd June 5, 2014